Form 4: Akero Therapeutics COO Sells Shares to Cover Tax Obligations

Akero Therapeutics' Chief Operating Officer, Jonathan Young, sold 2,493 shares of common stock for approximately $53.99 per share to satisfy tax withholding obligations related to restricted stock unit vesting.

Summary

• Jonathan Young, Chief Operating Officer of Akero Therapeutics, Inc. (AKRO), sold 2,493 shares of the company's common stock on June 10, 2025.
• The shares were sold at a weighted-average price of $53.993, with individual transaction prices ranging from $53.13 to $54.00.
• This sale was non-discretionary and executed to cover tax withholding obligations associated with the vesting of restricted stock units, in accordance with the company's 'sell-to-cover' policy.
• Following this transaction, Mr. Young directly beneficially owns 198,047 shares of Akero Therapeutics common stock.
• Additionally, 60,000 shares are held indirectly in three irrevocable trusts for the benefit of his children, for which Mr. Young disclaims beneficial ownership.

Sentiment

Score: 5

Explanation: The transaction is a routine, non-discretionary 'sell-to-cover' for tax obligations related to RSU vesting, which is a neutral event. It does not indicate a change in management's confidence or a strategic shift.

Positives

• The sale was non-discretionary and automatic, indicating it was not a voluntary divestment based on a negative outlook for the company.
• The transaction aligns with a standard 'sell-to-cover' policy for tax obligations related to RSU vesting, which is a common and expected practice for equity compensation.

Negatives

• The transaction resulted in a reduction of Jonathan Young's direct beneficial ownership of Akero Therapeutics common stock by 2,493 shares.

Risks

• No specific new risks are identified in this Form 4 filing beyond the inherent market risks associated with stock ownership.

Future Outlook

This Form 4 filing does not contain any forward-looking statements or guidance regarding the company's future outlook.

Management Comments

• The sale represents the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units.
• The Issuer has adopted a 'sell-to-cover' policy to satisfy the tax withholding obligations of the Reporting Person.
• Such sales were automatic and not at the discretion of the Reporting Person.
• The Reporting Person disclaims beneficial ownership of the shares held in irrevocable trusts for his children, and the filing of this report is not an admission that the Reporting Person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose.

Industry Context

This insider transaction is a routine event for publicly traded companies, reflecting standard compensation practices involving restricted stock units and associated tax obligations. It does not provide specific insights into broader industry trends or competitive dynamics within the biotechnology or pharmaceutical sector.

Related Party Transactions

• 60,000 shares are held in three irrevocable trusts (EA, CM, JL Irrevocable Trusts) for the benefit of the Reporting Person's children, with the Reporting Person's spouse as trustee. The Reporting Person disclaims beneficial ownership of these securities.

Stakeholder Impact

• Shareholders: Minimal direct impact as the sale was non-discretionary and for tax purposes, not indicative of a change in insider sentiment.
• Employees: No direct impact mentioned.
• Customers: No direct impact mentioned.
• Suppliers: No direct impact mentioned.
• Creditors: No direct impact mentioned.

Next Steps

• This document does not outline any specific future actions, events, or milestones for the company or the reporting person beyond the reported transaction.

Key Dates

Keywords

Akero Therapeutics, AKRO, Jonathan Young, Chief Operating Officer, COO, Insider Trading, Form 4, SEC Filing, Stock Sale, Restricted Stock Units, RSU Vesting, Tax Withholding, Sell-to-Cover